Explore our tests
Biomarkers
Androgen Receptor (AR) – The androgen receptor plays a crucial role in the development and progression of prostate cancer. AR biomarker testing is done to assess the expression levels of this receptor in prostate tissue. Elevated AR expression is linked to poor prognosis and more aggressive disease.
ERG – ERG is a gene that plays a role in regulating the growth and differentiation of prostate cells. Studies have shown that ERG overexpression is present in around 50% of prostate cancer cases, and it is associated with more aggressive disease.
BRCA1/2 – BRCA1/2 are genes that play a role in DNA repair. Mutations in these genes are commonly associated with increased risk for breast and ovarian cancers, but recent research has also shown that mutations in these genes can increase the risk for prostate cancer in men.
HRR Genes – HRR (Homologous Recombination Repair) genes play a crucial role in DNA repair. Mutations in these genes have been linked to an increased risk for prostate cancer. The HRR genes include genes such as ATM, CHEK2, RAD51, BRIP1, and PALB2.
Frequency of Mutation
For Patients
Prostate cancer affects the prostate which is a part of the male reproductive system. Prostate cancer can be classified as low, intermediate or high grade based on a prognostic Gleason score. This classification aids in treatment decisions. Early stage prostate cancer is usually treated with surgery and radiation while hormonal therapy and chemotherapy are used in later stages. Genetic testing is useful for late stage prostate cancer.
If you have metastatic prostate cancer
Certain prostate cancers have oncogenic alterations in genes in the Homologous Recombination Repair (HRR) pathway. The most common genes in this pathway are BRCA1 and BRCA2. Mutations in these genes are usually inherited, but in certain cases they may also arise in the tumor and hence testing your tumor tissue for such mutations can be beneficial. If a deleterious mutation is found in any of the genes in the HRR pathway, then it indicates a likely favorable response to a class of drugs known as PARP inhibitors.
If you have progressed on androgen deprivation therapy
Various ADT agents such as abiraterone and enzalutamide are used in metastatic prostate cancer. Sometimes a tumor responds to these treatments initially but later seems to lose response. In such cases testing for a specific alteration known as ARv7 can help determine whether ADT will be useful any more.
Test Portfolio
Test Name
No.of genes
Select
Final Diagnosis Panel (by IHC)
1
Germline Panel – Prostrate Cancer
12
Somatic BRCA Test
2
Homologous Recombination Repair Test (HRR)
14
Comprehensive Genomic Profiling – StrandAdvantage 500 Basic (DNA)
523
Comprehensive Genomic Profiling – StrandAdvantage 500 Advanced (DNA+RNA)
523
We provide genetic counselling to help you understand your test reports
Our certified genetic counselors will guide you through the test details and possible outcomes based on your family history.
Our genetic counselors will walk you through your genetic test report and explain the implications of your results and further plan of action
Our Helpline Number
+91 9980448044
Like, Comment, Follow, Share & Subscribe us on our social media channels
